Biofrontera (0DOL) AI Stock Analysis

Top Page

Biofrontera

(LSE:0DOL)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Gross MarginAn approximately 83% gross margin indicates that the core products retain substantial economic value after direct costs. If revenue can return to sustained growth, this margin profile could provide meaningful operating leverage and support future profitability as fixed costs are absorbed.

Negative Factors

Persistent Net LossesOngoing net losses show that the current revenue base is not yet sufficient to cover operating and other costs. This weakens internally funded growth, limits financial resilience, and makes a durable improvement in earnings dependent on scaling revenue or reducing expenses.

Biofrontera (0DOL) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 131.05M
Dividend Yield: ―
Average Volume (3M): 251
Price to Earnings (P/E): -1.5
Beta (1Y): -0.49
Revenue Growth: ―
EPS Growth: ―
Country: UK
Employees: 62
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Biofrontera Business Overview & Revenue Model

Company Description

Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the Unite...

Biofrontera Earnings Call Summary

Earnings Call Date:Jun 02, 2026(Q1-2026)|% Change Since:30.83%|Next Earnings Date:May 28, 2019

Earnings Call SentimentPositive

The call presented meaningful operational and clinical progress: double-digit revenue growth (17% YoY), a substantial gross margin expansion to ~80% following the strategic transaction, near-breakeven operating cash usage ($70k), strong clinical/regulatory milestones (sNDA accepted with PDUFA date, positive Phase III AK data, encouraging acne Phase II), and regained NASDAQ compliance. Offsetting these positives are persistent GAAP losses (net loss $4.8M), higher SG&A (up ~27%), patent/legal and manufacturing transition costs, modest cash reserves ($6.3M) with a going concern qualification, and exposure to tariff/supply risks. Overall, the highlights—particularly the margin improvement, cash-flow progress, and clinical/regulatory advances—meaningfully outweigh the lowlights, though execution and financing risks remain.

Positive Updates

Revenue Growth

Product revenues of $10.1M in Q1 2026, up ~17% versus $8.6M in Q1 2025, driven by ~16% Ameluz unit volume growth and a price increase implemented in Q4 2025 (price increase contributed ~ $0.2M).

Negative Updates

Net Loss and GAAP Earnings Pressure

Net loss widened to $4.8M (loss per share $0.41) in Q1 2026 versus $4.2M (loss per share $0.47) in Q1 2025, reflecting nonrecurring items and a $0.8M swing in fair value of warrant liabilities that adversely impacted GAAP results.

Company Guidance

Management guided a 2026 path to cash‑flow breakeven supported by Q1 results: product revenues $10.1M (+17% YoY from $8.6M), Ameluz volumes ~29,000 tubes (+16% from ~25,000), a Q1 price lift that added ~$0.2M, 32 RhodoLED lamps shipped (installed base ~773 lamps in 709 offices), and a gross margin of ~80% (vs ~62% YoY) driven by a ~40% decline in cost of goods ($3.1M to $1.8M) and a $1.2M earnout (earnout terms: 12% of net sales ≤ $65M, 15% > $65M); financials also showed adjusted EBITDA of -$3.6M (margin -35% vs -51%), operating loss $4.3M, net loss $4.8M ($0.41/sh), cash used in operations ~$70k (vs $4.1M), cash $6.3M (vs $6.4M), a $3.4M AR collection, expectation to file an sNDA for AK in Q3, a sBCC PDUFA on Sept 28, 2026, and a long‑term gross margin target of 80–85% (patent protection through 2043).

Biofrontera Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GB:0DOL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:EUZ	69Neutral	EUR 832.23M	16.63	19.49%	1.65%	4.42%	35.68%
DE:MRK	68Neutral	EUR 65.78B	27.76	8.08%	1.45%	-0.40%	-17.22%
DE:DMP	65Neutral	EUR 1.91B	13.92	22.38%	2.28%	0.39%	38.58%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:HPHA	41Neutral	EUR 98.71M	-3.30	200.64%	―	206.78%	-13.94%
DE:EVT	39Underperform	EUR 500.65M	-2.54	-26.46%	―	-7.72%	-26.61%

* General Sector Average

Performance Comparison

GB:0DOL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0DOL	Biofrontera AG	3.14	-11.16	-78.04%
DE:EUZ	Eckert & Ziegler Strahlen und Medizintechnik	13.30	-3.09	-18.88%
DE:EVT	Evotec AG (UK)	2.82	-4.19	-59.78%
DE:MRK	Merck KGaA	151.30	41.75	38.11%
DE:HPHA	Heidelberg Pharma AG	2.11	-0.87	-29.19%
DE:DMP	Dermapharm Holding	38.55	5.28	15.86%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Biofrontera AI Stock Analysis